---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-126509"
form_type: "8-K"
ticker: null
cik: "0001661460"
company_name: "Poseida Therapeutics, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:58:43.288741+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Poseida & Astellas/Xyphos enter allogeneic CAR-T collaboration; $50M upfront, $550M milestones

## Summary
- $50M upfront payment ($6M advanced for R&D); up to $550M in development/sales milestones plus low double-digit tiered royalties.
- Two allogeneic convertible CAR-T candidates targeting solid tumors combining Poseida’s platform with Xyphos’ ACCEL technology.
- Xyphos responsible for development/commercialization; Poseida performs research through IND-enabling data package.
- Expands existing relationship; Astellas made strategic investment in Poseida in August 2023.

## SEC filing metadata
- accession: 0001193125-24-126509
- form_type: 8-K
- cik: 0001661460
- company_name: Poseida Therapeutics, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/0001193125-24-126509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/d813637d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-126509
- JSON: https://secwatch.observer/filing/0001193125-24-126509.json
- Plain text: https://secwatch.observer/filing/0001193125-24-126509.txt

## Key facts
- Material Agreements
  Poseida Therapeutics, Inc. entered into Collaboration Agreement with Xyphos Biosciences, Inc. valued at $50.0 million (effective 2024-04-30).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Xyphos Biosciences, Inc.
  - Value: $50.0 million
  - Effective: 2024-04-30
  source text: On April 30, 2024, Poseida Therapeutics, Inc. (the “Company”) and Xyphos Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (“Xyphos”), entered into a collaboration and license agreement (the “Collaboration Agreement”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661460/000119312524126509/0001193125-24-126509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.